FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 355:1060-1061 September 7, 2006 Number 10 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Perspective by Sharpe, A. H. Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Suntharalingam, G. PubMed Citation

Clinical research can be a risky endeavor. In this issue of the Journal, Suntharalingam et al.¹ describe the events that occurred when six healthy volunteers received a dose (0.1 mg per kilogram of body weight) of TGN1412 — a superagonistic humanized monoclonal antibody that stimulates and expands T-cell populations independently of the ligation of the T-cell receptor. In all six patients, the cytokine-release syndrome developed, including multiorgan failure. Two of the patients required mechanical ventilation, and all received renal-replacement therapy. All six had severe hypotension, and peripheral ischemia developed in one patient to the extent that surgical treatment was required.

. . . [Full Text of this Article]

Source Information

This article was published at www.nejm.org on August 14, 2006.

This article has been cited by other articles:

• Mayor, S. (2006). In the eye of the storm. BMJ 333: 570-570 [Full Text]